Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.
N Engl J Med. 2022.
PMID: 36507686
Clinical Trial.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL.
Chari A, et al. Among authors: hilder bw.
Cancer. 2016 Nov 15;122(21):3327-3335. doi: 10.1002/cncr.30174. Epub 2016 Jul 19.
Cancer. 2016.
PMID: 27433944
Free PMC article.
Clinical Trial.
Item in Clipboard
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y.
Girgis S, et al. Among authors: hilder bw.
Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24.
Target Oncol. 2022.
PMID: 35749004
Free PMC article.
Clinical Trial.
Item in Clipboard
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y.
Girgis S, et al. Among authors: hilder bw.
Target Oncol. 2022 Sep;17(5):609. doi: 10.1007/s11523-022-00904-y.
Target Oncol. 2022.
PMID: 35913648
Free PMC article.
No abstract available.
Item in Clipboard
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, Fink D, Miao X, Chen Y, Stephenson T, Banerjee A, Hilder BW, Russell J, Infante J, Elsayed Y, Smit J, Goldberg JD.
Girgis S, et al. Among authors: hilder bw.
Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625.
Blood Adv. 2023.
PMID: 36006441
Free PMC article.
No abstract available.
Item in Clipboard
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Chari A, Askari E, Caers J, Costa LJ, Hilder BW, Krishnan A, Mateos MV, Minnema MC, Oriol A, Pillarisetti K, van de Donk NWCJ, Rodríguez-Otero P.
Chari A, et al. Among authors: hilder bw.
Future Oncol. 2023 Sep;19(27):1823-1840. doi: 10.2217/fon-2023-0332. Epub 2023 Jul 26.
Future Oncol. 2023.
PMID: 37492991
Free article.
Review.
Item in Clipboard
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S.
Shah JJ, et al. Among authors: hilder bw.
Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17.
Cancer. 2017.
PMID: 28817190
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite